2023-03-30 09:46:58 ET
- Candel Therapeutics press release ( NASDAQ: CADL ): Q4 GAAP EPS of -$0.18.
-
Research and Development Service Revenue, related party: Research and development service revenue, related party, for each of the fourth quarters and full- years ended December 31, 2022 and 2021 was $31,000 and $125,000, respectively.
- Research and Development Expenses: Research and development expenses were $5.0 million for the fourth quarter of 2022 compared to $3.9 million for the fourth quarter of 2021, and $20.8 million for the full-year 2022 compared to $15.2 million for the full-year 2021.
- Net loss for the fourth quarter of 2022 was $5.1 million compared to net income of $1.6 million for the fourth quarter of 2021, and included net other income of $3.0 million and $9.3 million
For further details see:
Candel Therapeutics GAAP EPS of -$0.18